Skip to content
AnalystLens

Neurocrine Biosciences 8-K Report, Executive Changes (Sep 28, 2026)

Reports
Leadership Changes
Filing Date
Filed September 28, 2026
Period End
September 25, 2026
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 8-K filed September 28, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. disclosed a leadership change in its executive team.

Its Board of Directors appointed Eiry W. Roberts, M.D., as Chief Medical Officer, succeeding Sanjay Keswani, M.D., effective September 28, 2026. The filing states that Dr. Keswani and the Board mutually agreed that his service as Chief Medical Officer would terminate as of September 25, 2026.

Dr. Keswani will be entitled to severance benefits under Section 4.1 of the Company's Executive Severance Plan, subject to the plan's terms. The Company will enter into an Amended and Restated Employment Agreement with Dr. Roberts, effective as of the transition date, which replaces his May 30, 2025 employment agreement, as amended on November 21, 2025. Under the new agreement, Dr. Roberts will receive an annual base salary of $825,000a and a target annual cash bonus equal to 60% of base pay for calendar year 2026.

He will also receive equity grants under the 2025 Equity Incentive Plan with target grant values of approximately $625,000b in stock options, $250,000 in restricted stock units, and $375,000 in performance-vesting restricted stock units. The equity grants are scheduled to be made two business days after the Company files its first Form 10-Q following the transition date, provided he remains employed. Dr. Roberts' existing equity awards will remain outstanding and continue vesting under their terms.

The summary in the filing is not the full agreement. The Company anticipates filing the complete Employment Agreement with its Quarterly Report on Form 10-Q for the quarter ending September 30, 2026. The filing also includes standard forward-looking statement cautions.

Key Highlights

  1. Eiry W. Roberts, M.D., was appointed Chief Medical Officer effective September 28, 2026, succeeding Sanjay Keswani, M.D.
  2. Dr. Keswani's service as Chief Medical Officer ended September 25, 2026, by mutual agreement with the Board.
  3. Dr. Keswani is entitled to severance benefits under Section 4.1 of the Executive Severance Plan, effective February 7, 2025.
  4. Dr. Roberts will receive an annual base salary of $825,000 and a target annual cash bonus of 60% of base pay for 2026.
  5. Dr. Roberts' equity grants have target values of approximately $625,000 in stock options, $250,000 in RSUs, and $375,000 in performance-vesting RSUs.
  6. Dr. Roberts' new Amended and Restated Employment Agreement replaces his May 30, 2025 agreement, as amended November 21, 2025.
  7. The full Employment Agreement is expected to be filed with the Form 10-Q for the quarter ending September 30, 2026.

Frequently Asked Questions

  1. Who is replacing Sanjay Keswani as Chief Medical Officer?

    The Board appointed Eiry W. Roberts, M.D., to succeed Dr. Keswani as Chief Medical Officer, effective September 28, 2026.

  2. When did Dr. Keswani's role end, and what severance is he receiving?

    Dr. Keswani's service as Chief Medical Officer terminated as of September 25, 2026, by mutual agreement with the Board. He is entitled to severance benefits under Section 4.1 of the Company's Executive Severance Plan, subject to the plan's terms.

  3. What compensation will Dr. Roberts receive?

    Dr. Roberts will receive a $825,000 annual base salary and a target annual cash bonus equal to 60% of base pay for 2026. He will also receive equity grants with target values of approximately $625,000 in stock options, $250,000 in RSUs, and $375,000 in performance-vesting RSUs.

  4. When will Dr. Roberts' equity grants be made?

    The equity grants will be made automatically on the date two business days after the Company files its first Form 10-Q following the September 28, 2026 transition date, provided Dr. Roberts remains employed on that date. The number of shares will depend on the Company's common stock price on the grant date.

  5. Where can investors find the full terms of Dr. Roberts' employment agreement?

    The Company anticipates filing the complete Amended and Restated Employment Agreement with its Quarterly Report on Form 10-Q for the three months ending September 30, 2026. The 8-K summary is qualified in its entirety by that complete text.